Overview Dividends

(CTVA) Corteva - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US22052L1044

Seeds, Traits, Crop Protection, Herbicides, Insecticides

Fertilizers & Agricultural Chemicals
Market Cap in USD: 44,739m

IPO / Inception: 2019-05-24
Return 12m vs S&P 500: 1.64%

EPS (Earnings per Share)

EPS CAGR: -10.35%
EPS Trend: -3.8%

Last SUE: 1.00
Qual. Beats: 3

Revenue

Rev. CAGR: -7.30%
Rev. Trend: -7.5%

Last SUE: 0.87
Qual. Beats: 1

Dividends

Dividend Yield	1.06%
Yield on Cost 5y	1.87%
Yield CAGR 5y	6.14%
Payout Consistency	100.0%
Payout Ratio	23.0%

Risk via 5d forecast
Volatility	24.8%
Value at Risk 5%th	36.7%
Relative Tail Risk	-10.20%

Reward TTM
Sharpe Ratio	0.63
Alpha	3.87
CAGR/Max DD	0.16

Character TTM
Hurst Exponent	0.433
Beta	0.623
Beta Downside	0.920

Drawdowns 3y
Max DD	31.90%
Mean DD	11.59%
Median DD	11.14%

Description: CTVA Corteva December 03, 2025

Corteva Inc. (NYSE: CTVA) operates globally in agricultural inputs through two core segments: Seed and Crop Protection. The Seed segment supplies advanced germplasm and trait technologies that boost yield, improve resistance to weather, pests and herbicides, and add nutritional value, while also delivering digital agronomy tools to help farmers optimise product choices and profitability. The Crop Protection segment markets herbicides, insecticides, nitrogen stabilisers and pasture-range herbicides, aiming to safeguard crops from weeds, insects, diseases and to enhance soil health via seed-applied solutions.

In FY 2023 the company generated roughly $6.2 billion in revenue, with the Crop Protection segment contributing about 55 % and Seed about 45 %. Corteva’s R&D spend remained near $900 million, reflecting its commitment to trait innovation and digital platforms-key drivers in a market where global grain demand is projected to rise 15 % by 2030 and climate-related yield volatility is increasing. Additionally, the firm’s exposure to commodity price cycles and its expanding presence in emerging markets (Latin America, Asia-Pacific) are material factors influencing earnings outlook.

For a deeper quantitative view of CTVA’s valuation metrics, the ValueRay platform offers a concise dashboard you may find useful.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (1.60b TTM) > 0 and > 6% of Revenue (6% = 1.05b TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 2.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 34.45% (prev 31.41%; Δ 3.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 3.20b > Net Income 1.60b (YES >=105%, WARN >=100%)

Net Debt (1.86b) to EBITDA (3.70b) ratio: 0.50 <= 3.0 (WARN <= 3.5)

Current Ratio 1.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (678.7m) change vs 12m ago -1.79% (target <= -2.0% for YES)

Gross Margin 46.11% (prev 43.51%; Δ 2.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 41.54% (prev 39.70%; Δ 1.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 12.89 (EBITDA TTM 3.70b / Interest Expense TTM 194.0m) >= 6 (WARN >= 3)

Altman Z'' 1.29

(A) 0.14 = (Total Current Assets 16.44b - Total Current Liabilities 10.42b) / Total Assets 42.20b

(B) 0.02 = Retained Earnings (Balance) 834.0m / Total Assets 42.20b

(D) -0.11 = Book Value of Equity -1.82b / Total Liabilities 16.74b

Total Rating: 1.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.80

1. Piotroski 8.0pt

2. FCF Yield 5.70%

3. FCF Margin 15.19%

4. Debt/Equity 0.17

5. Debt/Ebitda 0.50

6. ROIC - WACC (= -0.35)%

7. RoE 6.47%

8. Rev. Trend -7.48%

9. EPS Trend -3.81%

What is the price of CTVA shares?

As of December 22, 2025, the stock is trading at USD 66.31 with a total of 8,433,688 shares traded.
Over the past week, the price has changed by +0.65%, over one month by +1.45%, over three months by -4.68% and over the past year by +17.69%.

Is CTVA a buy, sell or hold?

Corteva has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CTVA.

Strong Buy: 13
Buy: 5
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CTVA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	77.7	17.2%
Analysts Target Price	77.7	17.2%
ValueRay Target Price	70.1	5.7%

CTVA Fundamental Data Overview December 17, 2025

Market Cap USD = 44.74b (44.74b USD * 1.0 USD.USD)
P/E Trailing = 26.6721
P/E Forward = 18.6567
P/S = 2.5611
P/B = 1.7717
P/EG = 0.8573
Beta = 0.738
Revenue TTM = 17.47b USD
EBIT TTM = 2.50b USD
EBITDA TTM = 3.70b USD
Long Term Debt = 1.69b USD (from longTermDebt, last quarter)
Short Term Debt = 2.69b USD (from shortTermDebt, last quarter)
Debt = 4.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.86b USD (from netDebt column, last quarter)
Enterprise Value = 46.53b USD (44.74b + Debt 4.37b - CCE 2.59b)
Interest Coverage Ratio = 12.89 (Ebit TTM 2.50b / Interest Expense TTM 194.0m)
FCF Yield = 5.70% (FCF TTM 2.65b / Enterprise Value 46.53b)
FCF Margin = 15.19% (FCF TTM 2.65b / Revenue TTM 17.47b)
Net Margin = 9.19% (Net Income TTM 1.60b / Revenue TTM 17.47b)
Gross Margin = 46.11% ((Revenue TTM 17.47b - Cost of Revenue TTM 9.41b) / Revenue TTM)
Gross Margin QoQ = 37.20% (prev 54.58%)
Tobins Q-Ratio = 1.10 (Enterprise Value 46.53b / Total Assets 42.20b)
Interest Expense / Debt = 1.05% (Interest Expense 46.0m / Debt 4.37b)
Taxrate = 16.76% (-62.0m / -370.0m)
NOPAT = 2.08b (EBIT 2.50b * (1 - 16.76%))
Current Ratio = 1.58 (Total Current Assets 16.44b / Total Current Liabilities 10.42b)
Debt / Equity = 0.17 (Debt 4.37b / totalStockholderEquity, last quarter 25.22b)
Debt / EBITDA = 0.50 (Net Debt 1.86b / EBITDA 3.70b)
Debt / FCF = 0.70 (Net Debt 1.86b / FCF TTM 2.65b)
Total Stockholder Equity = 24.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.80% (Net Income 1.60b / Total Assets 42.20b)
RoE = 6.47% (Net Income TTM 1.60b / Total Stockholder Equity 24.80b)
RoCE = 9.44% (EBIT 2.50b / Capital Employed (Equity 24.80b + L.T.Debt 1.69b))
RoIC = 7.30% (NOPAT 2.08b / Invested Capital 28.50b)
WACC = 7.65% (E(44.74b)/V(49.11b) * Re(8.31%) + D(4.37b)/V(49.11b) * Rd(1.05%) * (1-Tc(0.17)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.81%
[DCF Debug] Terminal Value 69.27% ; FCFE base≈2.30b ; Y1≈1.51b ; Y5≈689.1m
Fair Price DCF = 19.16 (DCF Value 12.95b / Shares Outstanding 675.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -3.81 | EPS CAGR: -10.35% | SUE: 1.00 | # QB: 3
Revenue Correlation: -7.48 | Revenue CAGR: -7.30% | SUE: 0.87 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.17 | Chg30d=-0.000 | Revisions Net=-1 | Analysts=9
EPS next Year (2026-12-31): EPS=2.96 | Chg30d=+0.108 | Revisions Net=+0 | Growth EPS=+31.6% | Growth Revenue=+3.5%

Additional Sources for CTVA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle